|
1
|
Donovan KA, Donovan HS, Cella D, Gaines
ME, Penson RT, Plaxe SC, von Gruenigen VE, Bruner DW, Reeve BB and
Wenzel L: Recommended patient-reported core set of symptoms and
quality-of-life domains to measure in ovarian cancer treatment
trials. J Natl Cancer Inst. 106:pii: dju1282014. View Article : Google Scholar
|
|
2
|
Chen CH, Chiu LH, Chan C and Liu WM:
Management of ovarian cancer in 14th gestational week of pregnancy
by robotic approach with preservation of the fetus. Gynecol Obstet
Invest. 80:139–144. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yang XJ, Zheng FY, Xu YS and Ou RY:
Ovarian cancer initially presenting with isolated ipsilateral
superficial inguinal lymph node metastasis: A case study and review
of the literature. J Ovarian Res. 7:202014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Shim SH, Kim DY, Seo MJ, Lee SW, Park JY,
Lee JJ, Kim JH, Kim YM, Kim YT and Nam JH: Preoperative fluorine 18
fluorodeoxyglucose tumoral uptake ratio between upper and lower
abdomen in primary advanced-stage ovarian cancer. Int J Gynecol
Cancer. 23:1383–1392. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Peng X, Wang P, Li S, Zhang G and Hu S:
Randomized clinical trial comparing octreotide and scopolamine
butylbromide in symptom control of patients with inoperable bowel
obstruction due to advanced ovarian cancer. World J Surg Oncol.
13:502015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mir MC, Stephenson AJ, Grubb RL III, Black
A, Kibel AS and Izmirlian G: Predicting risk of bladder cancer
using clinical and demographic information from prostate, lung,
colorectal, and ovarian cancer screening trial participants. Cancer
Epidemiol Biomarkers Prev. 22:2241–2249. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Nagano H, Muraoka M and Takagi K:
Recurrent ovarian cancer with multiple lymph nodes metastases
successfully treated with lymphadenectomy as secondary
cytoreductive surgery: A case report. Int J Surg Case Rep.
5:412–415. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bacalbasa N and Popescu I: Ovarian cancer
liver metastases-should we apply the principle of optimal
cytoreduction to the liver? A review. Hepatogastroenterology.
62:355–357. 2015.PubMed/NCBI
|
|
9
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Frampton JE: Olaparib: A review of its use
as maintenance therapy in patients with ovarian cancer. BioDrugs.
29:143–150. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ledermann J, Harter P and Gourley C:
Correction to Lancet Oncol 2014; 15: 856. Olaparib maintenance
therapy in patients with platinum-sensitive relapsed serous ovarian
cancer: A preplanned retrospective analysis of outcomes by BRCA
status in a randomised phase 2 trial. Lancet Oncol.
16:e1582015.PubMed/NCBI
|
|
12
|
Fu X, Zhang Y, Wang X, Chen M, Wang Y, Nie
J, Meng Y and Han W: Low dose decitabine combined with taxol and
platinum chemotherapy to treat refractory/recurrent ovarian cancer:
An open-label, single-arm, Phase I/II study. Curr Protein Pept Sci.
16:329–336. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
McGrail DJ, Khambhati NN, Qi MX, Patel KS,
Ravikumar N, Brandenburg CP and Dawson MR: Alterations in ovarian
cancer cell adhesion drive taxol resistance by increasing
microtubule dynamics in a FAK-dependent manner. Sci Rep.
5:95292015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Pettitt SJ, Rehman FL, Bajrami I, Brough
R, Wallberg F, Kozarewa I, Fenwick K, Assiotis I, Chen L, Campbell
J, et al: A genetic screen using the PiggyBac transposon in haploid
cells identifies Parp1 as a mediator of olaparib toxicity. PLoS
One. 8:e615202013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
McNeil EM, Ritchie AM and Melton DW: The
toxicity of nitrofuran compounds on melanoma and neuroblastoma
cells is enhanced by Olaparib and ameliorated by melanin pigment.
DNA Repair (Amst). 12:1000–1006. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bouquet W, Ceelen W, Adriaens E, Almeida
A, Quinten T, de Vos F, Pattyn P, Peeters M, Remon JP and Vervaet
C: In vivo toxicity and bioavailability of Taxol and a
paclitaxel/beta-cyclodextrin formulation in a rat model during
HIPEC. Ann Surg Oncol. 17:2510–2517. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Arany I, Clark JS, Reed D, Szabo I, Ember
I and Juncos LA: The role of p66shc in taxol- and dichloroacetic
acid-dependent renal toxicity. Anticancer Res. 33:3119–3122.
2013.PubMed/NCBI
|
|
18
|
Sun CC, Bodurka DC, Weaver CB, Rasu R,
Wolf JK, Bevers MW, Smith JA, Wharton JT and Rubenstein EB:
Rankings and symptom assessments of side effects from chemotherapy:
Insights from experienced patients with ovarian cancer. Support
Care Cancer. 13:219–227. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Faria A, Pestana D, Teixeira D, de Freitas
V, Mateus N and Calhau C: Blueberry anthocyanins and pyruvic acid
adducts: Anticancer properties in breast cancer cell lines.
Phytother Res. 24:1862–1869. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zu XY, Zhang ZY, Zhang XW, Yoshioka M,
Yang YN and Li J: Anthocyanins extracted from Chinese blueberry
(Vaccinium uliginosum L.) and its anticancer effects on DLD-1 and
COLO205 cells. Chin Med J (Engl). 123:2714–2719. 2010.PubMed/NCBI
|
|
21
|
Kanaya N, Adams L, Takasaki A and Chen S:
Whole blueberry powder inhibits metastasis of triple negative
breast cancer in a xenograft mouse model through modulation of
inflammatory cytokines. Nutr Cancer. 66:242–248. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Jeyabalan J, Aqil F, Munagala R, Annamalai
L, Vadhanam MV and Gupta RC: Chemopreventive and therapeutic
activity of dietary blueberry against estrogen-mediated breast
cancer. J Agric Food Chem. 62:3963–3971. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Thuresson ED, Lakkides KM and Smith WL:
PGG2, 11R-HPETE and 15R/S-HPETE are formed from different
conformers of arachidonic acid in the prostaglandin endoperoxide H
synthase-1 cyclooxygenase site. Adv Exp Med Biol. 507:67–72. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wilson AJ, Fadare O, Beeghly-Fadiel A, Son
DS, Liu Q, Zhao S, Saskowski J, Uddin MJ, Daniel C, Crews B, et al:
Aberrant over-expression of COX-1 intersects multiple
pro-tumorigenic pathways in high-grade serous ovarian cancer.
Oncotarget. 6:21353–21368. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lin Y, Cui M, Xu T, Yu W and Zhang L:
Silencing of cyclooxygenase-2 inhibits the growth, invasion and
migration of ovarian cancer cells. Mol Med Rep. 9:2499–2504.
2014.PubMed/NCBI
|
|
26
|
Hui X, Chen H, Zhang S, Ma X, Wang X and
Huang B: Antitumor activities of recombinant human interferon
(IFN)-λ1 in vitro and in xenograft models in vivo for colon cancer.
Cancer Lett. 311:141–151. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yang WL, Roland IH, Godwin AK and Xu XX:
Loss of TNF-alpha-regulated COX-2 expression in ovarian cancer
cells. Oncogene. 24:7991–8002. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Montales MT, Rahal OM, Kang J, Rogers TJ,
Prior RL, Wu X and Simmen RC: Repression of mammosphere formation
of human breast cancer cells by soy isoflavone genistein and
blueberry polyphenolic acids suggests diet-mediated targeting of
cancer stem-like/progenitor cells. Carcinogenesis. 33:652–660.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Esposito D, Chen A, Grace MH, Komarnytsky
S and Lila MA: Inhibitory effects of wild blueberry anthocyanins
and other flavonoids on biomarkers of acute and chronic
inflammation in vitro. J Agric Food Chem. 62:7022–7028. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Paulis G, Cavallini G, Giorgio GD,
Quattrocchi S, Brancato T and Alvaro R: Long-term multimodal
therapy (verapamil associated with propolis, blueberry, vitamin E
and local diclofenac) on patients with Peyronie's disease (chronic
inflammation of the tunica albuginea). Results of a controlled
study. Inflamm Allergy Drug Targets. 12:403–409. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ge I, Rudolph A, Shivappa N, Flesch-Janys
D, Hébert JR and Chang-Claude J: Dietary inflammation potential and
postmenopausal breast cancer risk in a German case-control study.
Breast. 24:491–496. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Khachatryan N and Kempen JH:
Immunosuppressive therapy and cancer risk in ocular inflammation
patients: Fresh evidence and more questions. Ophthalmology.
122:219–221. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Magnowska M, Zaborowski M, Surowiak P,
Nowak-Markwitz E, Zabel M and Spaczyński M: COX-2 expression
pattern is related to ovarian cancer differentiation and prognosis,
but is not consistent with new model of pathogenesis. Ginekol Pol.
85:335–341. 2014. View
Article : Google Scholar : PubMed/NCBI
|
